|
1
|
Wolmark N, Wang J, Mamounas E, Bryant J
and Fisher B: Preoperative chemotherapy in patients with operable
breast cancer: Nine-year results from national surgical adjuvant
breast and bowel project B-18. J Natl Cancer Inst Monogr.
30:96–102. 2001. View Article : Google Scholar
|
|
2
|
Bear HD, Anderson S, Brown A, Smith R,
Mamounas EP, Fisher B, Margolese R, Theoret H, Soran A, Wickerham
DL, et al: The effect on tumor response of adding sequential
preoperative docetaxel to preoperative doxorubicin and
cyclophosphamide: Preliminary results from National Surgical
Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol.
21:4165–4174. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rastogi P, Anderson SJ, Bear HD, Geyer CE,
Kahlenberg MS, Robidoux A, Margolese RG, Hoehn JL, Vogel VG, Dakhil
SR, et al: Preoperative chemotherapy: Updates of national surgical
adjuvant breast and bowel project protocols B-18 and B-27. J Clin
Oncol. 26:778–785. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gralow JR, Burstein HJ, Wood W, Hortobagyi
GN, Gianni L, von Minckwitz G, Buzdar AU, Smith IE, Symmans WF,
Singh B and Winer EP: Preoperative therapy in invasive breast
cancer: Pathologic assessment and systemic therapy issues in
operable disease. J Clin Oncol. 26:814–819. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Early Breast Cancer Trialists'
Collaborative Group (EBCTCG), . Peto R, Davies C, Godwin J, Gray R,
Pan HC, Clarke M, Cutter D, Darby S, McGale P, et al: Comparisons
between different polychemotherapy regimens for early breast
cancer: meta-analyses of long-term outcome among 100,000 women in
123 randomised trials. Lancet. 379:432–444. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
FrenchAdjuvantStudy Group: Benefit of a
high-dose epirubicin regimen in adjuvant chemotherapy for
node-positive breast cancer patients with poor prognostic factors:
5-year follow-up results of French Adjuvant Study Group 05
randomized trial. J Clin Oncol. 19:602–611. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bonneterre J, Roché H, Kerbrat P, Brémond
A, Fumoleau P, Namer M, Goudier MJ, Schraub S, Fargeot P and
Chapelle-Marcillac I: Epirubicin increases long-term survival in
adjuvant chemotherapy of patients with poor-prognosis,
node-positive, early breast cancer: 10-year follow-up results of
the french adjuvant study group 05 randomized trial. J Clin Oncol.
23:2686–2693. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
De Laurentiis M, Cancello G, D'Agostino D,
Giuliano M, Giordano A, Montagna E, Lauria R, Forestieri V,
Esposito A, Esposito A, et al: Taxane-based combinations as
adjuvant chemotherapy of early breast cancer: A meta-analysis of
randomized trials. J Clin Oncol. 26:44–53. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Martin M, Pienkowski T, Mackey J, Pawlicki
M, Guastalla JP, Weaver C, Tomiak E, Al-Tweigeri T, Chap L, Juhos
E, et al: Adjuvant docetaxel for node-positive breast cancer. N
Engl J Med. 352:2302–2313. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Roché H, Fumoleau P, Spielmann M, Canon
JL, Delozier T, Serin D, Symann M, Kerbrat P, Soulié P, Eichler F,
et al: Sequential adjuvant epirubicin-based and docetaxel
chemotherapy for node-positive breast cancer patients: The FNCLCC
PACS 01 trial. J Clin Oncol. 24:5664–5671. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Henderson IC, Berry DA, Demetri GD,
Cirrincione CT, Goldstein LJ, Martino S, Ingle JN, Cooper MR, Hayes
DF, Tkaczuk KH, et al: Improved outcomes from adding sequential
paclitaxel but not from escalating doxorubicin dose in an adjuvant
chemotherapy regimen for patients with node-positive primary breast
cancer. J Clin Oncol. 21:976–983. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mamounas EP, Bryant J, Lembersky B,
Fehrenbacher L, Sedlacek SM, Fisher B, Wickerham DL, Yothers G,
Soran A and Wolmark N: Paclitaxel after doxorubicin plus
cyclophosphamide as adjuvant chemotherapy for node-positive breast
cancer: Results from NSABP B-28. J Clin Oncol. 23:3686–3696. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Buzdar AU, Singletary SE, Valero V, Booser
DJ, Ibrahim NK, Rahman Z, Theriault RL, Walters R, Rivera E, Smith
TL, et al: Evaluation of paclitaxel in adjuvant chemotherapy for
patients with operable breast cancer: Preliminary data of a
prospective randomized trial. Clin Cancer Res. 8:1073–1079.
2002.PubMed/NCBI
|
|
14
|
Gradishar WJ, Tjulandin S, Davidson N,
Shaw H, Desai N, Bhar P, Hawkins M and O'Shaughnessy J: Phase III
trial of nanoparticle albumin-bound paclitaxel compared with
polyethylated castor oil-based paclitaxel in women with breast
cancer. J Clin Oncol. 23:7794–7803. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Blum JL, Savin MA, Edelman G, Pippen JE,
Robert NJ, Geister BV, Kirby RL, Clawson A and O'Shaughnessy JA:
Phase II study of weekly albumin-bound paclitaxel for patients with
metastatic breast cancer heavily pretreated with taxanes. Clin
Breast Cancer. 7:850–856. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Robidoux A, Buzdar AU, Quinaux E, Jacobs
S, Rastogi P, Fourchotte V, Younan RJ, Pajon ER, Shalaby IA, Desai
AM, et al: A phase II neoadjuvant trial of sequential nanoparticle
albumin-bound paclitaxel followed by
5-fluorouracil/epirubicin/cyclophosphamide in locally advanced
breast cancer. Clin Breast Cancer. 10:81–86. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Valachis A, Mauri D, Polyzos NP,
Chlouverakis G, Mavroudis D and Georgoulias V: Trastuzumab combined
to neoadjuvant chemotherapy in patients with HER2-positive breast
cancer: A systematic review and meta-analysis. Breast. 20:485–490.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shimada H, Ueda S, Saeki T, Shigekawa T,
Takeuchi H, Hirokawa E, Sugitani I, Sugiyama M, Takahashi T,
Matsuura K, et al: Neoadjuvant triweekly nanoparticle albumin-bound
paclitaxel followed by epirubicin and cyclophosphamide for Stage
II/III HER2-negative breast cancer: Evaluation of efficacy and
safety. Jpn J Clin Oncol. 45:642–649. 2015. View Article : Google Scholar : PubMed/NCBI
|
